Core Viewpoint - Gestala Technology is developing a non-invasive ultrasound brain-machine interface aimed at chronic pain management, with plans to initiate NMPA registration for Class III medical devices by the end of 2026 [2]. Group 1: Company Overview - Gestala Technology recently secured 150 million yuan in angel round financing, led by Guosheng Capital and Daotong Investment, with participation from several other institutions [3]. - The company was founded in January 2023 by Peng Lei and Chen Tianqiao, with a team of approximately 15 experts in various fields including acoustics, neuroscience, and AI [3]. Group 2: Technology and Mechanism - Current brain-machine interface solutions are categorized into invasive and non-invasive types, with ultrasound technology emerging as a promising non-invasive option that can target deep brain areas [4]. - Ultrasound technology has unique advantages, including the ability to modulate specific brain regions without damaging neurons, thanks to recent breakthroughs in low-intensity focused ultrasound [4][5]. - The core of ultrasound neuromodulation involves converting mechanical waves into bioelectrical signals that neurons can respond to, utilizing various physical effects such as thermal and cavitation effects [5][6]. Group 3: Clinical Applications and Challenges - Gestala Technology aims to address chronic pain management as its first clinical application, supported by existing data showing a 50% reduction in pain scores after a single 45-minute ultrasound session [7]. - The company is also exploring applications for mental health disorders and neurodegenerative diseases, collaborating with top hospitals for clinical research [7]. - Challenges include ensuring precise control of ultrasound parameters and overcoming limitations in time resolution for real-time applications [6][7]. Group 4: Future Development and Market Position - The company plans a phased approach to development, starting with non-invasive neuromodulation, followed by enhanced brain activity reading capabilities, and eventually integrating genetic editing technologies [8]. - Gestala Technology believes that China has unique advantages in the ultrasound brain-machine interface sector, including rich clinical resources and supportive national policies [8].